Effects of six‐month creatine supplementation on patient‐ and clinician‐reported outcomes, and tissue creatine levels in patients with <scp>post‐COVID</scp>‐19 fatigue syndrome

Abstract Dietary creatine has been recently put forward as a possible intervention strategy to reduce post‐COVID‐19 fatigue syndrome yet no clinical study so far evaluated its efficacy and safety for this perplexing condition. In parallel‐group, randomized placebo‐controlled double‐blind trial, we analyzed the effects of 6‐month supplementation (4 g monohydrate per day) on various patient‐ clinician‐reported outcomes, tissue levels in 12 patients with syndrome. Creatine intake induced significant increase vastus medialis muscle right parietal white matter compared baseline values at both 3‐month follow‐ups ( p &lt; .05). Two‐way analysis variance repeated measures revealed difference (treatment vs. time interaction) between interventions .05), group was superior placebo augment muscle, left frontal matter, matter. reduction general after 3 months = .04), significantly improved scores several syndrome‐related symptoms (e.g., ageusia, breathing difficulties, body aches, headache, difficulties concentrating) follow‐up Taking 6 appears improve bioenergetics attenuate features syndrome; additional studies are warranted confirm our findings cohorts.